Vitro, HemoGenix Amend Cell-based Assay Alliance | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vitro Diagnostics today announced that it has amended an agreement with HemoGenix covering stem cell analysis tools.

The amended agreement expands upon the original agreement to include development of stem cell culture media and high-performance toxicity assays for new cell-based tools for drug discovery and development. The firms also intend to align their respective quality programs to assure consistency, said Golden, Colo.-based Vitro.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.